Sandoz welcomes English High Court decision refuting GSK claims re AirFluSal® Forspiro® inhaler
Friday, October 4th, 2019 - Sandoz welcomes the recent decision of the English High Court* refuting GSK’s claim that sale of the AirFluSal® Forspiro® inhaler (launched in November 2015 in the United Kingdom), passed off the appearance of its Seretide® Accuhaler®.
All claims made by GSK have been dismissed by the Court. As such, the decision allows Sandoz to continue to market the inhaler in the UK. This decision is in line with decisions from other courts that also rejected GSK´s claims on the merits.
Tim de Gavre, Country Head for Sandoz in the UK, said: ‘This is a welcome decision that secures access for the NHS and its patients to appropriate medicines that help save money and drive long-term sustainability’.
Sandoz is committed to providing the best possible asthma and COPD treatment and to optimizing patient compliance in the UK and throughout Europe.
*Glaxo Wellcome UK Limited & Another v Sandoz Limited & Others  EWHC 2545 (Ch)